|
|
Article: MITOTIX AND THE DUPONT MERCK PHARMACEUTICAL COMPANY SIGN AGREEMENT TO DEVELOP CELL CYCLE-BASED DRUGS TO TREAT CANCER
- Article from:
- PR Newswire
- Article date:
- December 7, 1995
CopyrightCOPYRIGHT 1995 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass., and WILMINGTON, Del., Dec. 7 /PRNewswire/ -- Mitotix Incorporated and DuPont Merck today announced a collaborative agreement to develop and commercialize novel anti-cancer therapeutics that act on a group of enzymes called cyclin-dependent kinases (Cdks), that are essential for regulating the cell division cycle. Through the agreement, DuPont Merck could invest up to $55 million in Mitotix in the form of equity, research, development and clinical milestone payments.
The collaboration is initially focusing on three of Mitotix's proprietary molecular targets. Under the terms of the agreement, DuPont Merck receives exclusive worldwide rights to ...